Skip to main content
S

SynPlexity

This company develops a high-throughput gene synthesis platform that uses microdroplet technology to create multiplex gene libraries. This enables applications in therapeutics, biomanufacturing, agriculture, and climate systems, accelerating research and development in these fields.

Eugene, United States250+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Existing gene synthesis methods often struggle to produce large, diverse gene libraries in a cost-effective manner, hindering research and development in fields like therapeutics, biomanufacturing, and agriculture. Traditional methods can be expensive and time-consuming, limiting the scale and throughput of experiments.

Solution

SynPlexity offers a high-throughput gene synthesis platform leveraging microdroplet technology to create multiplex gene libraries. Their DropSynth microreactor technology enables efficient, large-scale synthesis while reducing costs and material usage. This allows researchers to explore a greater number of variants at the same price point, accelerating discovery and innovation in synthetic biology.

Target Audience

SynPlexity's primary customers are researchers and companies in the fields of protein engineering, biological AI model development, drug discovery, and functional screening.

Features

  • DropSynth microreactor technology for efficient and cost-effective gene synthesis
  • Ability to create gene libraries with sizes ranging from 1,536 to over 100,000 members
  • Capability to synthesize DNA fragments up to 1 kb or 1 kb+ in length
  • Turnaround time of fewer than 12 business days
  • In-house quality control using Next-Generation Sequencing (NGS)
  • Pricing starting as low as $10 per gene
This profile is AI-generated and may contain inaccuracies.